International Journal of Epidemiology 2003;32:592-599
© International Epidemiological Association 2003
Cancer |
Pulmonary function as a predictor of lung cancer mortality in continuing cigarette smokers and in quitters
1 Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
2 Division of Preventive and Behavioral Medicine, University of Massachusetts Medical School, Worcester, MA, USA.
3 Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA.
4 Department of Biostatistics and Epidemiology, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA (current address).
5 Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
Correspondence: LE Eberly, 420 Delaware St. SE, MMC 303, Minneapolis, MN, 55455, USA. E-mail: lynn{at}biostat.umn.edu
Background Forced expiratory volume in 1 second (FEV1) may be useful for identifying smokers at higher risk of lung cancer. We examined the association of FEV1 with lung cancer mortality (LCM) among cigarette smokers in the Multiple Risk Factor Intervention Trial (MRFIT).
Methods In all, 6613 MRFIT baseline smokers alive at trial end in 1982 had acceptable FEV1 measures and complete smoking history; men were classified as during-trial long-term quitters (N = 1292), intermittent quitters (1961), and never quitters (3360). Proportional hazards models for LCM were fit with quintiles of average FEV1, adjusted for age, height, race, smoking history, and other risk factors.
Results For long-term, intermittent, and never quitters respectively, mean baseline cigarettes/ day was 28, 32, and 35; trial-averaged FEV1 was 3201, 3146, and 3082 ml; and average decline in FEV1 was –46.0, –54.6, and –62.5 ml/year. With median post-trial mortality follow-up of 18 years, there were 363 lung cancer deaths. Age-adjusted LCM rates varied across FEV1 quintiles from 50 (lowest quintile) to 11 (highest quintile), 58 to 11, and 76 to 20, per 10 000 person-years, for long-term quitters, intermittent quitters, and never quitters, respectively. Multivariate adjusted hazard ratios for 100 ml higher FEV1 were 0.92 [P = 0.004], 0.95 [P = 0.003], and 0.95 [P < 0.0001] respectively.
Conclusions These results demonstrate the strong predictive value of FEV1 for lung cancer among cigarette smokers independent of smoking history; results did not differ by during-trial quit status. FEV1 may be a biological marker for smoking dose or it may be that genetic susceptibilities to both decreased FEV1 and lung cancer are associated.
Keywords Lung diseases, lung neoplasms, respiratory function tests, forced expiratory volume, smoking, risk factors, risk assessment
Accepted 14 March 2003
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. M. Chatila, B. M. Thomashow, O. A. Minai, G. J. Criner, and B. J. Make Comorbidities in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2008; 5(4): 549 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Stringer, M. Tobias, H. C. O'Neill, and C. C. Franklin Cigarette smoke extract-induced suppression of caspase-3-like activity impairs human neutrophil phagocytosis Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1572 - L1579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P Purdue, L. Gold, B. Jarvholm, M. C R Alavanja, M. H Ward, and R. Vermeulen Impaired lung function and lung cancer incidence in a cohort of Swedish construction workers Thorax, January 1, 2007; 62(1): 51 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Ryu and H.-J. Lee Effects of Comorbidity and Smoking on the Survival of Lung Cancer Patients J. Clin. Oncol., December 1, 2006; 24(34): 5468 - 5469. [Full Text] [PDF]
|
|
|
|
|
|
S Wasswa-Kintu, W Q Gan, S F P Man, P D Pare, and D D Sin Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis Thorax, July 1, 2005; 60(7): 570 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M L G Janssen-Heijnen, S Smulders, V E P P Lemmens, F W J M Smeenk, H J A A van Geffen, and J W W Coebergh Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer Thorax, July 1, 2004; 59(7): 602 - 607. [Abstract] [Full Text] [PDF]
|
|